

Beth Israel Lahey Health
Beth Israel Deaconess Medical Center
Division of Urologic Surgery

Spring 2019

Message from the Chief



We continue to move forward in 2019 focused on growth, integration and teamwork as part of a larger system, Beth Israel Lahey Health (BILH). We are looking forward to what the future holds in education, research, and practice as part of BILH. – **Aria F. Olumi, MD**

What's new in Education?

Introducing Our Independent Urology Residency Program

The BIDMC Division of Urologic Surgery has a long-standing tradition of educating and training residents. We are excited to announce the establishment of our independent Urology Residency Program. In July, we welcome our first residents to the program, Dr. Suprita Krishna (PGY 1) and Dr. Kenneth Softness (PGY2). Moving forward, we will participate in the AUA residency match program and fill our complement of two residents per year. Residents will complete rotations at BIDMC, BID-Needham, and Boston Children's Hospital. We are excited to continue our tradition of training future generations of urologic surgeons.

Learn more about our residency training program:

[View our program video](#)

[Visit our website](#)



Suprita Krishna, MD, PGY 1

Dr. Krishna completed her MBBS at Kasturba Medical College in Manipal, India, and MHA from the University of Minnesota. She joins us after her Clinical Junior Fellowship at Henry Ford Health System, Department of Urology in Michigan.



Kenneth A. Softness, MD, PGY 2

Dr. Softness completed medical school at Georgetown University School of Medicine. He joins us after completing one year as Diagnostic Radiology resident at Einstein Medical Center in Philadelphia, Pennsylvania.

Recruiting for 2020 Minimally Invasive Urologic Surgery Fellow


We are currently interviewing for our [William C. Dewolf Fellowship in Minimally Invasive Urologic Surgery](#). The fellowship is accredited by the Endourological Society and is directed by Andrew A. Wagner, MD, Chief of Minimally Invasive Urologic Surgery at BIDMC. The program involves one-year of advanced training in robotic and laparoscopic surgery with a focus on urologic oncology. Fellows also attend the [Harvard School of Public Health Program in Clinical Effectiveness](#), a 6 week full-time program in July and August.

To apply and for more information, please email [Dr. Wagner](#).

What's new in Research?

BIDMC Welcomes Olumi Lab

As of February 2019, the Olumi Lab moved to BIDMC's Research North. Olumi and research team, pictured below, are currently delving into prostate pathogenesis. [Learn more about the Olumi Lab](#).



Olumi Lab research team left to right: Bichen Xu, MD (Research Fellow, Visiting Researcher), Zongwei Wang, PhD (Instructor), Christina Sharkey, Hu Zhang, MD (Harvard Medical School Graduate Student), Pooja Unadkat, MBBS, MD (Research Staff)

Recent Publications

[Selecting Patients with Small Renal Masses for Active Surveillance: A Domain-Based Score from a Prospective Cohort Study](#). Jan 2019. J Urology. Sotimehin AE, Patel HD, Alam R, Gorin MA, Johnson MH, **Chang P, Wagner AA**, McKiernan JM, Allaf ME, Pierorazio PM.

[Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study \(PASS\)](#). Jan 2019. Prostate Cancer Prostatic Dis. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, **Wagner AA**, Carroll PR, Nelson PS, Lin DW.

[Use of delayed intervention for small renal masses initially managed with active surveillance](#). January 2019. Urol Oncol. Gupta M, Alam R, Patel HD, Semerjian A, Gorin MA, Johnson MH, **Chang P, Wagner AA**, McKiernan JM, Allaf ME, Pierorazio PM.

[Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS](#). Jan 2019. J Urol. Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, **Wagner A**, Zheng Y, Lin DW.

[Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study](#). Jan 2019. BJU Int. Alam R, Patel HD, Osumah T, Srivastava A, Gorin MA, Johnson MH, Trock BJ, **Chang P, Wagner AA**, McKiernan JM, Allaf ME, Pierorazio PM.

[Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis](#). Jan 2019. BMC Med Inform Decis Mak. Wilson LS, Blonquist TM, Hong F, Halpenny B, Wolpin S, **Chang P**, Filson CP, Master VA, Sanda MG, Chien GW, Jones RA, Krupski TL, Berry DL.

[Long-term \(more than 5 years\) outcomes of patients implanted with artificial urinary sphincter: A single-center experience](#). Jan 2019. Urol Ann. Abello A, **Das AK**.

[Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone](#). Feb 2019. J Clin Oncol. McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, **Chang P, Wagner AA**, Bubley GJ, Kibel AS, Taplin ME.

[Expanded Prostate Cancer Index Composite-26 \(EPIC-26\) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer](#). February 2019. Urology. Einstein DJ, Patil D, Chipman J, Regan MM, Davis K, Crociani CM, **Wagner AA**, Sanda MG, **Chang P**.

[Delayed Return of Ejaculatory Function in Adolescent Males Treated With Retroperitoneal Lymph Node Dissection and Adjuvant Therapy for Paratesticular Rhabdomyosarcoma](#). Feb. 2019. Urology. T Rague J, Varda BK, **Wagner AA**, Lee RS.

[Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study](#). Mar 2019. Mod Pathol. Cahill LC, Fujimoto JG, Giacomelli MG, Yoshitake T, Wu Y, Lin DI, Ye H, Carrasco-Zevallos OM, **Wagner AA**, Rosen S.

What's new in Practice?

Welcome to Boris Gershman, MD



We welcomed [Boris Gershman, MD](#), to the team on April 1st! Dr. Gershman transitioned to BIDMC Urologic Surgery from his role as Assistant Professor at The Warren Alpert Medical School of Brown University. Gershman received his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed residency training at the Massachusetts General Hospital followed by a Society of Urologic Oncology (SUO) fellowship at Mayo Clinic.

Gershman's clinical interests are in urologic oncology, including the management of prostate, kidney, bladder, and testis cancer. He has broad research interest in comparative effectiveness and health services research, with a particular focus on risk-stratification for urologic malignancies and quality measurement.

Urology at Beth Israel Deaconess HealthCare–Chelsea

As of April 23rd, we have expanded our provision of high-quality urologic care to the Chelsea community at [BIDHC–Chelsea](#).

Join Our Team!

We are actively recruiting for General Urologists at BIDMC and BID-Plymouth. Please contact [bidmcurology@bidmc.harvard.edu](#) if you are interested in learning more about these opportunities.

Beth Israel Deaconess
Medical Center



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Division of Urologic Surgery at Beth Israel Deaconess Medical Center
330 Brookline Avenue, Boston, MA 02215
617-667-3739 • [bidmc.org/urology](#) • [bidmcurology@bidmc.harvard.edu](#)

Share this email:



Manage your preferences | [Opt out](#) using TrueRemove®

Got this as a forward? [Sign up](#) to receive our future emails.

View this email [online](#).

330 Brookline Ave.
Boston, MA | 02215 US

This email was sent to .
To continue receiving our emails, add us to your address book.

emma